Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet
NCT06982963 is registered in ClinicalTrials.gov with Forte Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet
- Lead sponsor
- Forte Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 4, 2025
- Completion date
- February 28, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.